HLS Therapeutics Inc. (OTCMKTS:HLTRF) Shares Shorted: Short Interest Up 1,746.0% in October

HLS Therapeutics Inc. (OTCMKTS:HLTRF) saw a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,846 shares, an increase of 1,746.0% from the October 15th total of 100 shares. Based on an average trading volume of 4,910 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

HLS Therapeutics Stock Performance

Shares of OTCMKTS:HLTRF remained flat at $3.20 during midday trading on Tuesday. HLS Therapeutics has a 1-year low of $2.64 and a 1-year high of $3.70. The company’s 50 day simple moving average is $2.86 and its two-hundred day simple moving average is $3.09.

HLS Therapeutics Company Profile

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution. The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.